HTG Molecular Diagnostics, Inc. (HTGM) Trading Down 3.3%
Shares of HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) fell 3.3% on Friday . The company traded as low as $1.80 and last traded at $1.78. 326,444 shares were traded during trading, a decline of 18% from the average session volume of 397,629 shares. The stock had previously closed at $1.84.
A number of research firms have recently weighed in on HTGM. Zacks Investment Research lowered shares of HTG Molecular Diagnostics from a “hold” rating to a “sell” rating in a report on Tuesday, August 15th. ValuEngine upgraded shares of HTG Molecular Diagnostics from a “strong sell” rating to a “sell” rating in a report on Saturday, August 12th. Finally, HC Wainwright set a $6.00 target price on shares of HTG Molecular Diagnostics and gave the stock a “buy” rating in a report on Wednesday, August 9th. Two analysts have rated the stock with a sell rating, one has issued a hold rating and two have assigned a buy rating to the stock. HTG Molecular Diagnostics currently has a consensus rating of “Hold” and a consensus target price of $5.75.
The company’s market capitalization is $21.06 million. The stock has a 50-day moving average price of $1.87 and a 200-day moving average price of $1.87.
HTG Molecular Diagnostics (NASDAQ:HTGM) last released its quarterly earnings data on Tuesday, August 8th. The medical research company reported ($0.60) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.60). The company had revenue of $1.76 million during the quarter, compared to analysts’ expectations of $1.80 million. HTG Molecular Diagnostics had a negative net margin of 432.74% and a negative return on equity of 1,538.49%. On average, analysts anticipate that HTG Molecular Diagnostics, Inc. will post ($2.29) EPS for the current year.
In other news, major shareholder Holdings A/S Novo sold 1,149,813 shares of the company’s stock in a transaction that occurred on Friday, August 25th. The shares were sold at an average price of $1.81, for a total value of $2,081,161.53. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Over the last three months, insiders sold 1,659,998 shares of company stock valued at $3,073,696. 7.60% of the stock is owned by corporate insiders.
Several institutional investors and hedge funds have recently made changes to their positions in HTGM. UBS Group AG purchased a new stake in shares of HTG Molecular Diagnostics in the 1st quarter worth approximately $137,000. Two Sigma Securities LLC purchased a new stake in shares of HTG Molecular Diagnostics in the 1st quarter worth approximately $150,000. Granahan Investment Management Inc. MA purchased a new stake in shares of HTG Molecular Diagnostics in the 1st quarter worth approximately $228,000. Finally, Vanguard Group Inc. lifted its position in shares of HTG Molecular Diagnostics by 38.9% in the 2nd quarter. Vanguard Group Inc. now owns 135,234 shares of the medical research company’s stock worth $359,000 after purchasing an additional 37,841 shares during the period. 21.67% of the stock is owned by hedge funds and other institutional investors.
HTG Molecular Diagnostics Company Profile
HTG Molecular Diagnostics, Inc is a commercial-stage company that develops and markets a technology platform to facilitate the routine use of complex molecular profiling. The Company’s HTG Edge and HTG EdgeSeq platforms, consisting of instrumentation, consumables and software analytics, are used in sample profiling applications, including tumor profiling, molecular diagnostic testing and biomarker development.
Receive News & Ratings for HTG Molecular Diagnostics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HTG Molecular Diagnostics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.